Phathom Pharmaceuticals, Inc.
PHAT
$9.58
$0.404.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -99.07M | -157.30M | -221.25M | -274.55M | -330.15M |
| Total Depreciation and Amortization | 508.00K | 566.00K | 633.00K | 698.00K | 733.00K |
| Total Amortization of Deferred Charges | 3.34M | 3.16M | 3.01M | 2.83M | 2.65M |
| Total Other Non-Cash Items | 51.86M | 58.00M | 63.20M | 71.25M | 74.60M |
| Change in Net Operating Assets | 6.67M | -1.92M | -12.38M | -25.46M | -22.52M |
| Cash from Operations | -36.69M | -97.49M | -166.78M | -225.23M | -274.69M |
| Capital Expenditure | -219.00K | -272.00K | -229.00K | -147.00K | -164.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -219.00K | -272.00K | -229.00K | -147.00K | -164.00K |
| Total Debt Issued | 173.25M | 173.25M | -- | 24.75M | 24.75M |
| Total Debt Repaid | -229.05M | -229.05M | -- | -- | -- |
| Issuance of Common Stock | 127.67M | 124.20M | 1.64M | 1.67M | 123.43M |
| Repurchase of Common Stock | -2.05M | -2.05M | -1.93M | -564.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.82M | 66.35M | -288.00K | 25.86M | 148.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.91M | -31.41M | -167.29M | -199.52M | -126.67M |